Ma Songjiang's Form 4 filing
Gyre Therapeutics, Inc. (GYRE) · filed May 14, 2025
- Accession no.
- 0001140361-25-018927
- Filed
- May 14, 2025
- Trade date
- May 12-13, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $43.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ma SongjiangCIK 0001985547 | Director, Officer (President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 12, 2025 | Common Stock | SSaleDisposed | −2,000 | $10.56 | −$21,120 | 2,822,844 | Indirect | |
| May 13, 2025 | Common Stock | SSaleDisposed | −2,000 | $11.37 | −$22,740 | 2,820,844 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.